RxDoctor Payments Data

Dolores Gunn, MD

Family Medicine · East Saint Louis, ILNPI 1740247360

Payments from drug & device makers

$3,921in general payments, 2019–2025

Across 165 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$327
  • AstraZeneca$271
  • EMD Serono, Inc.$197
  • Amgen$129
  • Janssen Scientific Affairs, LLC$125
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,914100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,921 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$45,893
Medicare patients
216
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala28$121,011
FarxigaDapagliflozin Propanediol89$100,318
JardianceEmpagliflozin32$38,918
EliquisApixaban31$33,309
JanuviaSitagliptin Phosphate30$20,528
XareltoRivaroxaban20$18,481
OzempicSemaglutide12$15,282
TrulicityDulaglutide12$14,779
MyrbetriqMirabegron12$14,137
SymbicortBudesonide/Formoterol Fumarate28$8,347
Combivent RespimatIpratropium/Albuterol Sulfate12$7,510
Breo ElliptaFluticasone/Vilanterol15$6,253
Albuterol Sulfate HfaAlbuterol Sulfate252$5,912
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$5,845
Atorvastatin Calcium376$2,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$327$121,01128 claims
AstraZenecaFarxiga, Symbicort$271$108,665117 claims
Boehringer IngelheimJardiance, Combivent Respimat$113$46,42844 claims
PfizerEliquis$75$33,30931 claims
MerckJanuvia$24$20,52830 claims
Johnson & JohnsonXarelto$113$18,48120 claims
Novo NordiskOzempic$49$15,28212 claims
Lilly USA, LLCTrulicity$13$14,77912 claims
Astellas Pharma US IncMyrbetriq$22$14,13712 claims
GSKBreo Ellipta$105$6,25315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in East Saint Louis

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →